Literature DB >> 18362511

A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation.

H Falhammar1, M Thorén, K Hagenfeldt.   

Abstract

A 31-yr-old woman presenting with a history of hirsutism, amenorrhea, and infertility was previously assumed to have polycystic ovary syndrome. A new gynecological-endocrine evaluation demonstrated elevated testosterone/SHBG ratio, serum 17-hydroxyprogesterone (17-OHP), and urinary pregnantriol. She was diagnosed with non-classic congenital adrenal hyperplasia. In spite of treatment with dexamethasone and fludrocortisone in doses that suppressed adrenal androgens and 17-OHP into normal range or below, she did not ovulate. Clomiphene citrate and then FSH/hCG treatment in several cycles gave no consistent ovulation. Progesterone levels remained elevated throughout the cycles indicating a possible contribution from the adrenals. Oral glucose tolerance was normal, but the homeostasis model assessment index indicated insulin resistance. With metformin 1500 mg daily the index decreased remarkably from 2.77 to 0.96 with a few ovulations but no pregnancy occurred. Three cycles of IVF treatment thereafter were unsuccessful. Three months after the last in vitro fertilization (IVF) cycle, still on dexamethasone, fludrocortisone, and metformin, her menstruations became regular and she thereafter became pregnant. During pregnancy metformin was discontinued and dexamethasone replaced with prednisolone. Mild gestational diabetes developed and insulin was given. A healthy boy was born at term by elective Cesarean section. A CYP21- gene analysis had not indicated any of the known mutations but after gene sequencing a novel mutation was found, namely R233G. This case confirms the necessity of adding an analysis of 17-OHP when evaluating women with hirsutism and menstrual disturbances and if an elevated value is found, the advantage of performing a mutation analysis to facilitate counseling and decisions on treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362511     DOI: 10.1007/BF03345586

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

1.  High frequency of nonclassical steroid 21-hydroxylase deficiency.

Authors:  P W Speiser; B Dupont; P Rubinstein; A Piazza; A Kastelan; M I New
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

2.  Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  T A Bachega; A E Billerbeck; J A Marcondes; G Madureira; I J Arnhold; B B Mendonca
Journal:  Clin Endocrinol (Oxf)       Date:  2000-05       Impact factor: 3.478

Review 3.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

4.  Prevalence of and markers for the attenuated form of congenital adrenal hyperplasia and hyperprolactinemia masquerading as polycystic ovarian disease.

Authors:  F Benjamin; S Deutsch; H Saperstein; V L Seltzer
Journal:  Fertil Steril       Date:  1986-08       Impact factor: 7.329

5.  Nonclassical congenital adrenal hyperplasia and the polycystic ovarian syndrome.

Authors:  M I New
Journal:  Ann N Y Acad Sci       Date:  1993-05-28       Impact factor: 5.691

6.  R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversions.

Authors:  A Helmberg; M T Tusie-Luna; M Tabarelli; R Kofler; P C White
Journal:  Mol Endocrinol       Date:  1992-08

7.  Subnormal androgen and elevated progesterone levels in women treated for congenital virilizing 21-hydroxylase deficiency.

Authors:  J Helleday; B Siwers; E M Ritzén; K Carlström
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

8.  The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia.

Authors:  Nuri Kamel; Vedia Tonyukuk; Rifat Emral; Demet Corapçioğlu; Mehmet Baştemir; Sevim Güllü
Journal:  Endocr J       Date:  2003-12       Impact factor: 2.349

9.  Steroid 21-hydroxylase deficiency: three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations.

Authors:  A Wedell; E M Ritzén; B Haglund-Stengler; H Luthman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

10.  Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

Authors:  E Bonora; S Kiechl; J Willeit; F Oberhollenzer; G Egger; G Targher; M Alberiche; R C Bonadonna; M Muggeo
Journal:  Diabetes       Date:  1998-10       Impact factor: 9.461

View more
  6 in total

1.  Non-functioning adrenal incidentalomas caused by 21-hydroxylase deficiency or carrier status?

Authors:  Henrik Falhammar
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

Review 2.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

Review 3.  Clinical outcomes in the management of congenital adrenal hyperplasia.

Authors:  Henrik Falhammar; Marja Thorén
Journal:  Endocrine       Date:  2012-01-07       Impact factor: 3.633

Review 4.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

Review 5.  Biochemical and genetic diagnosis of 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Anna Wedell; Anna Nordenström
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

6.  Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.

Authors:  Jan Idkowiak; Stephen O'Riordan; Nicole Reisch; Ewa M Malunowicz; Felicity Collins; Michiel N Kerstens; Birgit Köhler; Luitgard Margarete Graul-Neumann; Maria Szarras-Czapnik; Mehul Dattani; Martin Silink; Cedric H L Shackleton; Dominique Maiter; Nils Krone; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2010-12-29       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.